Other
Wamd
0
Pipeline Programs↗
4
Active Trials↗
2
Companies Involved↗
wAMD is an early-stage landscape with 0 programs across 2 companies. The most active players are Beijing Anlong Biopharmaceutical Co., Ltd., Guangzhou Jiayin Biotech Ltd.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
5
clinical trials
Active, not recruiting3 · 60%
Enrolling by invitation1 · 20%
Unknown status1 · 20%
Clinical Trials
Trial Activity
Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD
Active, not recruiting·—·N/A·NCT04932980·80 enrolled
Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD
Active, not recruiting·BBeijing Anlong Biopharmaceutical Co., Ltd.·Phase 1/2·NCT06707753·21 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)